{"database": "lobbying", "table": "lobbying_activities", "rows": [[2870180, "f4bc27cb-ed05-458d-82b9-b05fc8a8e4b2", "Q3", "PUBLIC CITIZEN", 32362, "PUBLIC CITIZEN", 2022, "third_quarter", "PHA", "Drug price patent licensing executive action, INSULIN act, Licensing Government owned COVID technologies, Exercising executive licensing authorities to lower drug prices, HR 7900-NDAA amendment on Public protection of insulin for DOD, reconciliation drug price reform, and drug price negotiation provisions, Executive action to expand monkey pox Vaccine access, Global Covid 19 funding, HR 5376-Inflation reduction Act-drug pricing reform, insulin and drug price negotiation provisions, global and domestic monkey pox funding, Prescription Drugs affordability and access act, We PAID Act, USG support for mRNA hub", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 70000, 0, 0, "2022-10-18T10:10:22-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2870180"], "units": {}, "query_ms": 0.4581599496304989, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}